Valuation: Processa Pharmaceuticals, Inc.

Market Cap 4.52M 4.04M 3.77M 3.42M 6.44M 438M 6.51M 45.26M 17.7M 223M 16.99M 16.62M 716M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value -1.01M -904K -843K -766K -1.44M -98.02M -1.46M -10.12M -3.96M -49.81M -3.8M -3.72M -160M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.18%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Processa Pharmaceuticals, Inc.

1 day-12.22%
1 week-26.40%
Current month-27.74%
1 month-40.45%
3 months-39.85%
6 months-60.10%
Current year-58.85%
1 week 1.04
Extreme 1.041
1.63
1 month 1.04
Extreme 1.041
2.12
Current year 1.04
Extreme 1.041
3.8
1 year 1.04
Extreme 1.041
11.08
3 years 1.04
Extreme 1.041
450
5 years 1.04
Extreme 1.041
4,125
10 years 1.04
Extreme 1.041
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 2023-08-07
Investor Relations Contact 60 2011-03-28
Chief Administrative Officer 61 2017-10-03
Director TitleAgeSince
Chairman 73 2011-03-28
Chairman 60 2022-08-15
Director/Board Member 56 2020-02-12
Date Insider Type Main position Quantity % Market Cap. Importance
8/8/26 Exercice

Chief Executive Officer

3,200 0.1156%
7/26/26 Other

Chief Financial Officer

11,883 0.4293%
7/26/26 Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
+4.44%-26.40%-87.93%-98.72% 4.52M
-3.19%-3.19%+44.60%+87.98% 72.13B
+3.68%-10.25%+5.36%+56.70% 49.41B
+2.04%+1.24%+5.22%+33.47% 47.24B
-1.63%-8.25%+298.16%+644.35% 40.32B
+0.94%+0.26%+27.52%+29.73% 42.61B
+0.64%-2.40%+4.07%+102.26% 39.81B
-2.13%-2.18%+7.51%+50.31% 30.52B
+2.79%-4.44%-11.37%-15.29% 23.13B
+3.42%+7.93%+17.97%-0.04% 21.09B
Average -0.58%-4.96%+31.11%+89.08% 36.63B
Weighted average by Cap. +0.33%-3.85%+47.59%+118.02%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.58M -9.87M -8.97M -16.87M -1.15B -17.04M -119M -46.36M -583M -44.49M -43.53M -1.88B -13.56M -12.11M -11.3M -10.26M -19.32M -1.31B -19.5M -136M -53.06M -668M -50.93M -49.82M -2.15B
Net Debt -1.12M -998K -931K -846K -1.59M -108M -1.61M -11.18M -4.37M -55.01M -4.2M -4.11M -177M -5.54M -4.94M -4.61M -4.19M -7.88M -536M -7.96M -55.38M -21.66M -272M -20.79M -20.34M -876M
Projected Income Statement - Annual - Processa Pharmaceuticals, Inc.
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
26-10-09 US$1.210 -10.37% 127,839
26-10-08 US$1.350 -4.93% 12,803
26-10-07 US$1.420 -6.58% 12,904
26-10-06 US$1.520 +2.01% 18,585
26-10-05 US$1.490 -7.45% 25,737

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Processa Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. PCSA Stock